GSK, Vi­iV of­fer sneak peek of PhI­II da­ta on in-house two-drug HIV com­bo, tout­ing non-in­fe­ri­or­i­ty

Press­ing on with its am­bi­tious goal to out­shine Gilead in the HIV space, Glax­o­SmithK­line is now armed with pos­i­tive da­ta on its two-drug reg­i­men from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA